These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 32588182)

  • 21. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
    Preziosa P; Rocca MA; Nozzolillo A; Moiola L; Filippi M
    J Neurol; 2021 Aug; 268(8):2697-2699. PubMed ID: 33216223
    [No Abstract]   [Full Text] [Related]  

  • 22. Teaching Neuro
    Tsivgoulis G; Papadimitropoulos GN; Katsanos AH; Zompola C; Safouris A; Kargiotis O; Voumvourakis K
    Neurology; 2017 Oct; 89(15):e188-e189. PubMed ID: 28993534
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    Chevalier J; Chamoux C; Hammès F; Chicoye A
    PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data.
    Hauer L; Sellner J
    Drug Des Devel Ther; 2022; 16():3915-3927. PubMed ID: 36388086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    Kogel AK; Gold R; Schneider R
    J Neurol; 2021 Nov; 268(11):4374-4375. PubMed ID: 34175973
    [No Abstract]   [Full Text] [Related]  

  • 28. Comorbidity influences therapeutic approach in multiple sclerosis.
    Capone F; Ferraro E; Florio L; Marcoccia A; Di Lazzaro V; Di Battista G
    Clin Neurol Neurosurg; 2017 Apr; 155():14-16. PubMed ID: 28212926
    [No Abstract]   [Full Text] [Related]  

  • 29. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
    Deeks ED
    Drugs; 2016 Feb; 76(2):243-54. PubMed ID: 26689201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis.
    Amato MP; Goretti B; Brescia Morra V; Gallo P; Zaffaroni M; Onofrj M; Cocco E; Borriello G; Zipoli V; Trojano M
    Neurol Sci; 2020 Nov; 41(11):3185-3193. PubMed ID: 32358701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
    Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
    Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dimethyl fumarate: a case of improvement of alcoholic steatohepatitis in an elderly psoriatic patient.
    Filippi F; Sacchelli L; DI Altobrando A; Pileri A; Bardazzi F
    Ital J Dermatol Venerol; 2022 Oct; 157(5):448-449. PubMed ID: 34282861
    [No Abstract]   [Full Text] [Related]  

  • 35. What should we expect from multiple sclerosis therapy? Results of an integrated analysis of delayed-release dimethyl fumarate pivotal trials.
    Lanzillo R
    Eur J Neurol; 2017 May; 24(5):661-662. PubMed ID: 28332255
    [No Abstract]   [Full Text] [Related]  

  • 36. Venous thromboembolism in multiple sclerosis: a report of two cases with pulmonary embolism on dimethyl fumarate and available data from adverse event reporting systems. Time to include disease modifying drugs in the equation?
    Papathanasiou A; Abdel-Fahim R; Gilmore C; Evangelou N
    Clin Neurol Neurosurg; 2020 May; 192():105726. PubMed ID: 32062308
    [No Abstract]   [Full Text] [Related]  

  • 37. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).
    Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S
    Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating relapsing multiple sclerosis with dimethyl fumarate.
    McCarty DJ
    Nurse Pract; 2017 Jul; 42(7):8-10. PubMed ID: 28622251
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis.
    Lorefice L; Fenu G; Cabras F; Frau J; Coghe GC; Loi L; Marrosu MG; Cocco E
    Mult Scler Relat Disord; 2016 May; 7():65-7. PubMed ID: 27237760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.